The independent medical news service

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

The BONSAI trial has demonstrated encouraging efficacy and manageable toxicity of cabozantinib in treatment-naïve patients with metastatic collecting duct renal cell carcinoma.

The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.